KANGHUA BIOLOGICAL(SZ:300841) Xin Lang Cai Jing·2025-10-31 03:18Group 1 - The core viewpoint of the news is that Kanghua Biological has seen a 5% increase in stock price, reaching 77.25 yuan per share, with a trading volume of 203 million yuan and a turnover rate of 2.24%, resulting in a total market capitalization of 10.038 billion yuan [1] - Kanghua Biological, established on April 2, 2004, and listed on June 16, 2020, is primarily engaged in the comprehensive research, development, and operation of vaccines, with 99.99% of its main business revenue coming from non-immunization planning vaccines [1] Group 2 - Among the top ten circulating shareholders of Kanghua Biological, a fund under Southern Fund holds a position. The Southern CSI 1000 ETF (512100) reduced its holdings by 11,100 shares in the third quarter, now holding 850,600 shares, which accounts for 0.72% of the circulating shares [2] - The Southern CSI 1000 ETF (512100) was established on September 29, 2016, with a latest scale of 76.63 billion yuan. Year-to-date returns are 27.12%, ranking 2130 out of 4216 in its category, while the one-year return is 25.9%, ranking 2007 out of 3889 [2] - The fund manager of Southern CSI 1000 ETF (512100) is Cui Lei, who has been in the position for 6 years and 360 days, managing total assets of 122.76 billion yuan, with the best fund return during the tenure being 182.39% and the worst being -15.93% [2]